CORRECTING and REPLACING MultiBank Group Continues Its Global Expansion by Obtaining a Regulatory License in the Dubai International Financial Centre (DIFC)
12.10.2020 16:11:00 EEST | Business Wire | Press release
Fourth paragraph, first sentence of release dated October 11, 2020, should read: The MultiBank Group is now one of the largest financial derivatives groups in the world with an annual turnover of over US$ 1.9 Trillion... (instead of The MultiBank Group is now one of the largest financial derivatives groups in the world with a daily turnover of over US$ 1.9 Trillion...). Additionally, the multimedia has been updated to reflect new images.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201011005065/en/
MultiBank Group continues its global expansion by obtaining the DFSA regulatory license in the DIFC. (Graphic: Business Wire)
The updated release reads:
MULTIBANK GROUP CONTINUES ITS GLOBAL EXPANSION BY OBTAINING A REGULATORY LICENSE IN THE DUBAI INTERNATIONAL FINANCIAL CENTRE (DIFC)
MultiBank Group, one of the largest online financial derivatives providers worldwide, represented by its subsidiary, MEX Australia Pty Ltd, has secured a reputable and strategic commercial license from the Dubai Financial Services Authority (DFSA).
The addition of this coveted license extends the group’s regulatory arsenal to include heavily regulated companies regulated by ASIC in Australia, BaFin in Germany, FMA in Austria, CNMV in Spain, FSC in the British Virgin Islands and CIMA in the Cayman Islands.
With the opening of the new office in the DIFC, the MultiBank Group now operates through 21 offices in 5 continents.
The MultiBank Group is now one of the largest financial derivatives groups in the world with an annual turnover of over US$ 1.9 Trillion and Gross Profit of US$85.6 million in 2019, facilitating over 90,000 trades per day and services over 280,000 customers worldwide.
Naser Taher, Chairman of MultiBank Group, said:
“The DFSA license marks yet another momentous occasion for MultiBank Group and is a testament to the strength of our group and commitment to the MENA region. The DFSA approval underscores our dedication to continue to provide our retail and institutional clients with world class services and the highest level of security of funds”.
Courtney Fitzsimmons, CEO of MEX Australia Pty Ltd, added:
“We have thoroughly enjoyed working with the DFSA throughout this process and proudly take a position here in the DIFC. In this evolving market we are thrilled to add to our regulatory arsenal, and look forward to making our mark in Dubai”
For more information about the MultiBank Group, please visit www.multibankfx.com.
For more information about MEX Australia Pty Ltd (DIFC Branch), please visit www.mexexchange.ae
About MultiBank Group:
MultiBank Group was established in California, USA in 2005. It boasts a daily trading volume of over US $7.2 billion and services an extensive client base of over 280,000 customers across 90 countries. Since its launch, MultiBank Group has evolved into one of the largest online financial derivatives providers worldwide. The group offers a combination of the most advanced and award-winning trading platforms, up to a 500:1 leverage on CFD trading with products including Shares, Commodities, Indices, Digital Assets, Metals and Foreign Exchange (Forex).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201011005065/en/
Contact information
Media Enquiries:
Ruby Korver | Communications Officer
MultiBank Group
Email: ruby.korver@multibankfx.com
Phone: +971 487 513 50
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom